Physician-scientist Charles M. Rudin, Chief of the Thoracic Oncology Service, leads research that focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models including patient-derived xenografts. These studies are integrated with early phase clinical trials.
Charles M. Rudin, MD, PhD
Professor
Research Focus
Physician-scientist Charles Rudin focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models.Education
MD, PhD, University of Chicago Pritzker School of MedicineLab Members
John Poirier
Lab co-Director
Viola Allaj
Senior Research Technician
Metamia Ciampricotti
Postdoctoral Researcher
Christopher Hulton
Graduate Student
Corrin Wohlhieter
Graduate Student
Nisarg Shah
Research Assistant/Lab Manager
Joseph Chan
Thoracic Oncology Fellow
Andrew Chow
Medical Oncology Fellow
Emily Costa
Graduate Student
Victoria Lai
Assistant Attending, Thoracic Oncology Service
Michael Offin
Assistant Attending, Thoracic Oncology Service
Triparna Sen
Assistant Attending/Lab Co-Director
Kathryn M. Tully
Graduate Student
Fathema Uddin
Research Technician
Álvaro Quintanal Villalonga
Research Fellow
Publications
- Ruscetti M, Leibold J, Bott MJ, Fennell M, Kulick A, Salgado NR, Chen CC, Ho YJ, Sanchez-Rivera FJ, Feucht J, Baslan T, Tian S, Chen HA, Romesser PB, Poirier JT, Rudin CM, de Stanchina E, Manchado E, Sherr CJ, Lowe SW. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science. 362(6421):1416-1422. 2018.
- Laird JH, Lok BH, Ma J, Bell A, de Stanchina E, Poirier JT, Rudin CM. Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts. Clin Cancer Res. 24(20):5143-5152. 2018.
